Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)

Tumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by system...

Descripción completa

Detalles Bibliográficos
Autor principal: Glasser, Chana L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678818/
https://www.ncbi.nlm.nih.gov/pubmed/29159035
http://dx.doi.org/10.1016/j.lrr.2017.10.002
_version_ 1783277517320224768
author Glasser, Chana L.
author_facet Glasser, Chana L.
author_sort Glasser, Chana L.
collection PubMed
description Tumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by systemic chemotherapy, however, there have been case reports of TLS following intrathecal (IT) chemotherapy, all in patients with acute lymphoblastic leukemia (ALL)/lymphoma. Here, we report the first case of a patient with acute myelogenous leukemia (AML) who developed TLS following a single dose of IT cytosine arabinoside (Ara-C).
format Online
Article
Text
id pubmed-5678818
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-56788182017-11-20 Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML) Glasser, Chana L. Leuk Res Rep Article Tumor Lysis Syndrome (TLS) is a well-known complication of induction therapy for hematologic malignancies. It is characterized by rapid breakdown of malignant white blood cells (WBCs) leading to metabolic derangements and serious morbidity if left untreated. Most commonly, TLS is triggered by systemic chemotherapy, however, there have been case reports of TLS following intrathecal (IT) chemotherapy, all in patients with acute lymphoblastic leukemia (ALL)/lymphoma. Here, we report the first case of a patient with acute myelogenous leukemia (AML) who developed TLS following a single dose of IT cytosine arabinoside (Ara-C). Elsevier 2017-10-23 /pmc/articles/PMC5678818/ /pubmed/29159035 http://dx.doi.org/10.1016/j.lrr.2017.10.002 Text en © 2017 The Author http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Glasser, Chana L.
Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title_full Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title_fullStr Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title_full_unstemmed Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title_short Tumor Lysis Syndrome (TLS) following intrathecal chemotherapy in a child with acute myelogenous leukemia (AML)
title_sort tumor lysis syndrome (tls) following intrathecal chemotherapy in a child with acute myelogenous leukemia (aml)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678818/
https://www.ncbi.nlm.nih.gov/pubmed/29159035
http://dx.doi.org/10.1016/j.lrr.2017.10.002
work_keys_str_mv AT glasserchanal tumorlysissyndrometlsfollowingintrathecalchemotherapyinachildwithacutemyelogenousleukemiaaml

Ejemplares similares